Literature DB >> 31613205

An amino acid change in nsP4 of chikungunya virus confers fitness advantage in human cell lines rather than in Aedes albopictus.

Jolene Yin Ling Fu1, Chong Long Chua1, Indra Vythilingam2, Wan Yusoff Wan Sulaiman2, Hui Vern Wong1, Yoke Fun Chan1, I-Ching Sam1.   

Abstract

Chikungunya virus (CHIKV) has caused large-scale epidemics of fever, rash and arthritis since 2004. This unprecedented re-emergence has been associated with mutations in genes encoding structural envelope proteins, providing increased fitness in the secondary vector Aedes albopictus. In the 2008-2013 CHIKV outbreaks across Southeast Asia, an R82S mutation in non-structural protein 4 (nsP4) emerged early in Malaysia or Singapore and quickly became predominant. To determine whether this nsP4-R82S mutation provides a selective advantage in host cells, which may have contributed to the epidemic, the fitness of infectious clone-derived CHIKV with wild-type nsP4-82R and mutant nsP4-82S were compared in Ae. albopictus and human cell lines. Viral infectivity, dissemination and transmission in Ae. albopictus were not affected by the mutation when the two variants were tested separately. In competition, the nsP4-82R variant showed an advantage over nsP4-82S in dissemination to the salivary glands, but only in late infection (10 days). In human rhabdomyosarcoma (RD) and embryonic kidney (HEK-293T) cell lines coinfected at a 1 : 1 ratio, wild-type nsP4-82R virus was rapidly outcompeted by nsP4-82S virus as early as one passage (3 days). In conclusion, the nsP4-R82S mutation provides a greater selective advantage in human cells than in Ae. albopictus, which may explain its apparent natural selection during CHIKV spread in Southeast Asia. This is an unusual example of a naturally occurring mutation in a non-structural protein, which may have facilitated epidemic transmission of CHIKV.

Entities:  

Keywords:  Aedes albopictus; Southeast Asia; chikungunya virus; human cell lines; nsP4

Year:  2019        PMID: 31613205     DOI: 10.1099/jgv.0.001338

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  4 in total

Review 1.  The origin and continuing adaptive evolution of chikungunya virus.

Authors:  Mohamad S Hakim; Luthvia Annisa; Faris M Gazali; Abu T Aman
Journal:  Arch Virol       Date:  2022-08-20       Impact factor: 2.685

2.  Persistence of chikungunya ECSA genotype and local outbreak in an upper medium class neighborhood in Northeast Brazil.

Authors:  Jaqueline Goes de Jesus; Gabriel da Luz Wallau; Maricelia Lima Maia; Joilson Xavier; Maria Aparecida Oliveira Lima; Vagner Fonseca; Alvaro Salgado de Abreu; Stephane Fraga de Oliveira Tosta; Helineide Ramos do Amaral; Italo Andrade Barbosa Lima; Paloma Viana Silva; Daiana Carlos Dos Santos; Aline Sousa de Oliveira; Siane Campos de Souza; Melissa Barreto Falcão; Erenilde Cerqueira; Laís Ceschini Machado; Mariana Carolina Sobral; Tatiana Maria Teodoro Rezende; Mylena Ribeiro Pereira; Felicidade Mota Pereira; Zuinara Pereira Gusmão Maia; Rafael Freitas de Oliveira França; André Luiz de Abreu; Carlos Frederico Campelo de Albuquerque E Melo; Nuno Rodrigues Faria; Rivaldo Venâncio da Cunha; Marta Giovanetti; Luiz Carlos Junior Alcantara
Journal:  PLoS One       Date:  2020-01-08       Impact factor: 3.240

3.  Fast Expansion of the Asian-Pacific Genotype of the Chikungunya Virus in Indonesia.

Authors:  Yusnita Mirna Anggraeni; Triwibowo Ambar Garjito; Mega Tyas Prihatin; Sri Wahyuni Handayani; Kusumaningtyas Sekar Negari; Ary Oktsari Yanti; Muhammad Choirul Hidajat; Dhian Prastowo; Tri Baskoro Tunggul Satoto; Sylvie Manguin; Laurent Gavotte; Roger Frutos
Journal:  Front Cell Infect Microbiol       Date:  2021-04-21       Impact factor: 5.293

4.  Chikungunya virus: Molecular epidemiology of nonstructural proteins in Pakistan.

Authors:  Nazish Badar; Aamer Ikram; Muhammad Salman; Muhammad Masroor Alam; Massab Umair; Yasir Arshad; Nighat Mushtaq; Hamza Ahmad Mirza; Abdul Ahad; Umer Farooq; Muhammad Talha Yasin; Javaria Qazi
Journal:  PLoS One       Date:  2021-12-23       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.